ArticleStem cells and development2015
VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients.
Article in Stem cells and development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- FOXA2 in cancer: from fundamental biology to clinical translation.Frontiers in oncology · 2026Review
- LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.Oncogene · 2025Article
- Article
- GFPT2 promotes paclitaxel resistance in epithelial ovarian cancer cells via activating NF-κB signaling pathway.Open life sciences · 2025Article
- Article
- ∆Np63α inhibits Rac1 activation and cancer cell invasion through suppression of PREX1.Cell death discovery · 2024Article
- Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials.Cancers · 2021Review
- A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models.Journal of advanced research · 2021Article
- Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden.F1000Research · 2021Article
- Article
- Integrative analysis of transcription factors and microRNAs in ovarian cancer cell spheroids.Journal of ovarian research · 2020Article
- Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics.Diagnostics (Basel, Switzerland) · 2019Article
- An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma.OncoTargets and therapy · 2019Article
- CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells.Stem cell reports · 2018Article
- A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer.BMC biology · 2018Article
- Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.Journal of Cancer · 2018Article
- Are ovarian cancer stem cells the target for innovative immunotherapy?OncoTargets and therapy · 2018Review
- The Rac GTPase in Cancer: From Old Concepts to New Paradigms.Cancer research · 2017Review
- Ovarian cancer stem cells: still an elusive entity?Molecular cancer · 2017Review
- STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer.Medicine · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian carcinoma is a highly lethal malignancy due to frequent relapse and drug resistance. Cancer stem cells (CSCs) are thought to contribute significantly to disease relapse and drug resistance. In this study, a subpopulation of CSCs of ovarian carcinoma was isolated and the genes differentially expressed in these cells were identified to characterize CSCs and to find candidate biomarkers. Ovarian carcinoma cells from patients were primarily cultured, and spheroid-forming cells (SFCs) were isolated. The characteristic genes of SFCs were identified through cDNA microarray and validation by quantitative real-time polymerase chain reaction and immunohistochemistry, and the association of their expression with clinicopathologic parameters was analyzed. GSC (4.26-fold), VAV3 (7.05-fold), FOXA2 (12.06-fold), LEF1 (17.26-fold), COMP (21.33-fold), GRIN2A (9.36-fold), CD86 (23.14-fold), PYY (4.18-fold), NKX3-2 (10.35-fold), and PDK4 (74.26-fold) were significantly upregulated in SFCs compared with parental cancer cells. With validation for human ovarian carcinomas, LEF1, PYY, NKX3-2, and WNT3A were significantly upregulated in chemoresistant cancers compared with chemosensitive cancers. Overexpression of LEF1, VAV3, and NKX3-2 was significantly associated with distant metastasis by immunohistochemistry. VAV3 overexpression was an independent poor survival indicator (hazard ratio=15.27, P<0.05) by multivariate Cox analysis. The further functional assay revealed that VAV3 knockdown regulated CSC activation and ovarian cancer cell proliferation and sensitized paclitaxel (PTX)-resistant cancer cells to PTX treatment. Taken together, we identified by high-throughput analysis of CSCs that VAV3 overexpression is a novel biomarker for poor prognosis and survival in ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.